170105-16-5

• 常用中文名：咪达那新
• 常用英文名：Imidafenacin
• CAS号：170105-16-5
• 分子式：C₂₀H₂₁N₃O
• 分子量：319.400
• 相关类别： 信号通路 G 蛋白偶联受体/G 蛋白 由mAChR
• 发布时间：2018-09-01 04:29:57
• 更新时间：2026-07-10 12:11:36
• Imidafenacin(KRP-197; ONO-8025)是一种有效的和选择性的M3受体抑制剂，Kb值为0.317nM，对M2受体Kb值稍弱。

名称

• 中文名: 咪达那新
• 英文名: 4-(2-methylimidazol-1-yl)-2,2-diphenylbutanamide
• 中文别名: 咪达非那辛; 氘10-伊米达芬酸; 咪达那新|||KRP-197|||ONO-8025; 咪达那新API; 咪达那新 [IMIDAFENACIN]; Imidafenacin试剂; 4-(2-甲基-1H-咪唑-1-基)-2,2-二苯基丁酰胺; 化合物：Imidafenacin (KRP-197); 咪达那新,10 MM DMSO 溶液; 盐酸咪哒那新; 化合物:Imidafenacin (KRP-197); 咪达那新及各步中间体
• 英文别名: 2-Methyl-α,α-diphenyl-1H-iMidazole-1-butanaMide; Midana new API; 1H-IMidazole-1-butanaMide,2-Methyl-a,a-diphenyl; 4-(2-METHYL-1H-IMIDAZOL-1-YL)-2,2-DIPHENYLBUTANAMIDE; Imidafenacin-d10; 4-(2-Methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide; 4-(2-methyL; Uritos; IMidafenacin DISCONTINUED-PATENTED PRODUCT; Imidafenacin, 10 mM in DMSO; Staybla; Imidafenacin (JAN/INN); 4-(2-Methyl-1-iMidazolyl)-2,2- diphenylbutanaMide; Midanasine; [14C]-Imidafenacin; 4-(2-Methyl-imidazol-1-yl)-2,2-diphenyl-butyramide; C20H21N3O Imidafenacin 170-5; 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutyramide; )-2,2-diphenyL; KRP-197; ONO-8025; D10-Imidafenacin; Midanacin; 1H-Imidazole-1-butanamide, 2-methyl-α,α-diphenyl; Uritos (TN); Staybla (TN)

物化性质

• 密度: 1.1±0.1 g/cm3
• 沸点: 579.7±50.0 °C at 760 mmHg
• 分子式: C₂₀H₂₁N₃O
• 分子量: 319.400
• 闪点: 304.4±30.1 °C
• 精确质量: 319.168457
• PSA: 61.90000
• LogP: 2.42
• 蒸汽压: 0.0±1.6 mmHg at 25°C
• 折射率: 1.603
• 储存条件: 2-8℃

生物活性

• 描述: Imidafenacin(KRP-197; ONO-8025)是一种有效的和选择性的M3受体抑制剂,Kb值为0.317nM,对M2受体Kb值稍弱。
• 相关类别:
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 由mAChR
  信号通路 >> 神经信号通路 >> mAChR
  研究领域 >> 神经疾病
• 参考文献:

  [1]. Miyachi H, et al. Synthesis and antimuscarinic activity of a series of 4-(1-Imidazolyl)-2,2-diphenylbutyramides: discovery of potent and subtype-selective antimuscarinic agents. Bioorg Med Chem. 1999 Jun;7(6):1151-61.

  [2]. Yamazaki T, et al. Imidafenacin has no influence on learning in nucleus basalis of Meynert-lesioned rats. Naunyn Schmiedebergs Arch Pharmacol. 2013 Dec;386(12):1095-102.

合成路线

214777-43-2 ~32% 170105-16-5

文献：Kyorin Pharmaceutical Co., Ltd. Patent: US5932607 A1, 1999 ;

562091-56-9 ~86% 170105-16-5

文献：KYORIN PHARMACEUTICAL CO., LTD. Patent: EP1845091 A1, 2007 ; Location in patent: Page/Page column 4 ; EP 1845091 A1

893421-54-0 ~89% 170105-16-5

文献：KYORIN PHARMACEUTICAL CO., LTD. Patent: EP1845091 A1, 2007 ; Location in patent: Page/Page column 5 ; EP 1845091 A1

893421-55-1 ~77% 170105-16-5

文献：KYORIN PHARMACEUTICAL CO., LTD. Patent: EP1845091 A1, 2007 ; Location in patent: Page/Page column 6 ; EP 1845091 A1

39186-58-8 ~% 170105-16-5

文献：Bioorganic and Medicinal Chemistry Letters, , vol. 9, # 20 p. 3003 - 3008

86-29-3 ~% 170105-16-5

文献：Bioorganic and Medicinal Chemistry Letters, , vol. 9, # 20 p. 3003 - 3008